SECOND CALL OPTION AMENDMENT AGREEMENT dated as of January 28, 2021 Between LIGAND PHARMACEUTICALS INCORPORATED and BARCLAYS BANK PLCSecond Call Option Amendment Agreement • February 24th, 2021 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • New York
Contract Type FiledFebruary 24th, 2021 Company Industry JurisdictionTHIS SECOND CALL OPTION AMENDMENT AGREEMENT (this “Agreement”) with respect to the Call Option Confirmations (as defined below) is made as of January 28, 2021 between Ligand Pharmaceuticals Incorporated (“Company”) and Barclays Bank PLC (“Dealer”).
SECOND CALL OPTION AMENDMENT AGREEMENT dated as of January 28, 2021 Between LIGAND PHARMACEUTICALS INCORPORATED and GOLDMAN SACHS & CO. LLCSecond Call Option Amendment Agreement • February 24th, 2021 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • New York
Contract Type FiledFebruary 24th, 2021 Company Industry JurisdictionTHIS SECOND CALL OPTION AMENDMENT AGREEMENT (this “Agreement”) with respect to the Call Option Confirmations (as defined below) is made as of January 28, 2021 between Ligand Pharmaceuticals Incorporated (“Company”) and Goldman Sachs & Co. LLC (“Dealer”).